# Vaxcyte (PCVX) — Earnings

PCVX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/pcvx/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q4 2025 |
| Period end | Dec 31, 2025 |
| EPS actual | −$1.81 |
| EPS estimate | −$1.53 |
| EPS surprise | −18.32% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Feb 24, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1649094/000164909426000005/pcvx-20260224.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/format/5cbe400c-01a9-25db-e7f9-c2983f8b859b.html) |

Vaxcyte's most recent report in the table covers Q4 2025 and was released on February 24, 2026. The company posted a loss of $1.81 per share, wider than the $1.53 loss expected, a miss of 18.32%. A year earlier, in Q4 2024, the loss was $1.02 per share. No revenue was reported for the quarter, and no revenue estimate was given.

Every quarter in the table is a loss, and losses have widened over time. The smallest was $0.41 per share in Q4 2020 and Q1 2021. Annual losses grew from $1.93 per share in 2021 to $3.44 in 2022 and $4.14 in 2023, before easing to $3.80 in 2024. The largest quarterly loss was $1.83 in Q4 2023. The table has no row for Q3 2025, so there is no full-year 2025 total; the three quarters shown add up to a loss of $4.07 per share. Vaxcyte beat the EPS estimate in 11 of the 20 quarters shown.

The table holds no results after the February 2026 report. In past years Vaxcyte reported first-quarter results between May 7 and May 11, and second-quarter results between August 6 and August 11. The next figures shown will be for Q1 2026.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q4 2025 | Feb 24, 2026 | −$1.53 | −$1.81 | -18.32% | — | — |
| Q2 2025 | Aug 6, 2025 | −$1.16 | −$1.22 | -5.17% | — | — |
| Q1 2025 | May 7, 2025 | −$1.06 | −$1.04 | 2.02% | — | — |
| Q4 2024 | Feb 25, 2025 | −$1.11 | −$1.02 | 7.82% | — | — |
| Q3 2024 | Nov 5, 2024 | −$1.10 | −$0.83 | 24.60% | — | — |
| Q2 2024 | Aug 6, 2024 | −$0.98 | −$1.10 | -12.75% | — | — |
| Q1 2024 | May 8, 2024 | −$1.13 | −$0.85 | 24.70% | — | — |
| Q4 2023 | Feb 27, 2024 | −$1.05 | −$1.83 | -73.56% | — | — |
| Q3 2023 | Nov 6, 2023 | −$0.84 | −$0.91 | -8.63% | — | — |
| Q2 2023 | Aug 8, 2023 | −$0.75 | −$0.70 | 6.04% | — | — |
| Q1 2023 | May 8, 2023 | −$0.82 | −$0.70 | 14.85% | — | — |
| Q4 2022 | Feb 27, 2023 | −$0.93 | −$1.03 | -10.75% | — | — |
| Q3 2022 | Nov 7, 2022 | −$0.84 | −$0.93 | -11.15% | — | — |
| Q2 2022 | Aug 8, 2022 | −$0.69 | −$0.80 | -15.94% | — | — |
| Q1 2022 | May 9, 2022 | −$0.63 | −$0.68 | -8.50% | — | — |
| Q4 2021 | Feb 28, 2022 | −$0.56 | −$0.55 | 1.79% | — | — |
| Q3 2021 | Nov 10, 2021 | −$0.55 | −$0.51 | 6.71% | — | — |
| Q2 2021 | Aug 11, 2021 | −$0.52 | −$0.46 | 12.10% | — | — |
| Q1 2021 | May 11, 2021 | −$0.51 | −$0.41 | 19.61% | — | — |
| Q4 2020 | Mar 29, 2021 | −$0.54 | −$0.41 | 24.07% | — | — |

## Frequently Asked Questions

### When did Vaxcyte (PCVX) last report earnings?

Vaxcyte last reported on Feb 24, 2026, covering fiscal Q4 2025.

### Did PCVX beat earnings estimates?

No. Vaxcyte reported EPS of −$1.81 for Q4 2025 against a −$1.53 estimate — a 18.32% miss.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).